30 closest matches · ranked by relevance
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Mantle Cell Lymphoma
Primary: Overall Response Rate — 92 percentage of patients
Mantle Cell Lymphoma
Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants
Lymphoma
Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…
Lymphoma
Primary: Progression-free Survival — 90 percentage of participants
Mantle Cell Lymphoma
Primary: Overall Response Rate (ORR) at the Completion of Induction Chemotherapy, Which is the Percent of Complete Responses (CR) Plus Percent of Partial Responses (PR). — 90…
Mantle-Cell Lymphoma
Primary: Progression-Free Survival (PFS) — 8 years
Mantle Cell Lymphoma
Primary: Complete Response Rate to Induction Therapy — 64 percentage of participants
Mantle Cell Lymphoma · Lymphoma, Mantle Cell
Primary: Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) — 23.5…
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Non-Hodgkin's Lymphoma
Primary: ORR — 88; 81 percentage of patients
Untreated Mantle Cell Lymphoma
Primary: Number of Participants With Toxicity — 8 participants
Lymphoma, Mantle-Cell
Primary: Correlation Coefficient Between Change From Baseline in Fluoro-L-thymidine Positron Emission Tomography (FLT-PET) Maximum Standard Uptake Value (SUVmax) and in…
Lymphoma, Mantle Cell · Mantle Cell Lymphoma
Primary: Progression Free Survival (PFS) — 27.2; 33.5; 7.8 Months
Lymphoma
Primary: Progression-free Survival Rate — 91; 78; 69 percentage of participants
Lymphoma
Primary: Rate of Immunological Response to Vaccination — 0; 15 participants
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Mantle-Cell Lymphoma
Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg
Lymphoma
Primary: Progression-Free Survival (PFS) — 4.8; 3.7; 1.8 months — p=<0.0001
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Contiguous Stage II Mantle Cell Lymphoma · Noncontiguous Stage II Mantle Cell Lymphoma · Stage I Mantle Cell Lymphoma
Primary: Complete Response (CR) Rate — 0.68 proportion
Lymphoma · Mantle Cell Lymphoma · Indolent Lymphoma
Primary: Progression-free Survival at 2 Years — 15 Participants
Lymphoma
Primary: Overall Survival at 100 Days Post Transplant (Number of Surviving Participants) — 16; 19 participants
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Mantle Cell Lymphoma · Untreated
Primary: 3-year Progression-free Survival (PFS) — 63 % of pts progression-free survival
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Bortezomib (Phase I) — 1.3 mg/m^2
Mantle Cell Lymphoma
Primary: Progression Free Survival (PFS) — 437.0; 751.0 Days — p=<0.001